Jump to main content
News

A leukemia drug kills cancerous T-cells while sparing normal immunity

January 25, 2012
Researchers report that low-dose Campath (alemtuzumab) not only treats patients with L-CTCL but does so without increasing their risk of infections. Read more
Reading level: Grade 12
EurekAlert!, the online, global news service operated by AAAS, the science society

Explore Our Science Videos

Quick Links X
Top
Free science fair projects.